|
|
Vaccine Detail
|
Human Influenza Vaccine |
| Vaccine Information |
- Vaccine Name: Human Influenza Vaccine
- Target Pathogen: Influenza virus
- Target Disease: Influenza (flu)
- Type: Live, attenuated vaccine
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: influenza virus (general(
- Adjuvant:
- Preparation: "adjuvant is co-administered with vaccine" --> article discusses adjuvant prep, not vaccine prep ... assuming that it is same creation as FLUAD flu vaccine (Shukla et al., 2018)
- Immunization Route: Intramuscular injection (i.m.)
|
| Host Response |
|
Baboon Response
- Immune Response: "Activation of the JAKs that are associated with the IFNAR results in tyrosine phosphorylation of STAT1 (signal transducer and activator of transcription 1) and STAT2; this leads to the formation of IFN-stimulated gene factor 3 (ISGF3) complexes comprised of STAT1-STAT2-IRF9 multimers.11 These complexes translocate to the nucleus and bind IFN-stimulated response elements (ISREs) to initiate gene transcription.12,13 An increase in expression of genes associated with this IFN gene signature, including LY6E, MX1, OAS3, IFI44L, IFI6, and IFITM3, has been linked to the early phases after vaccination" (Shukla et al., 2018)
|
| References |
Shukla et al., 2018: Shukla NM, Arimoto KI, Yao S, Fan JB, Zhang Y, Sato-Kaneko F, Lao FS, Hosoya T, Messer K, Pu M, Cottam HB, Carson DA, Hayashi T, Zhang DE, Corr M. Identification of Compounds That Prolong Type I Interferon Signaling as Potential Vaccine Adjuvants. SLAS discovery : advancing life sciences R & D. 2018; 23(9); 960-973. [PubMed: 29751735].
|
|
